| Outcome Measures: |
Primary: Safety and tolerability assessed by incidence and severity of adverse events, A summary of SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module, up to 15 weeks | Secondary: Area under the plasma concentration versus time curve (AUC), PK parameters after administration of of TG103, Day1, 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78|glycosylated hemoglobin (HbA1c), Pharmacodynamic (PD) parameters after administration of of TG103, Day15, 29, 43, 57,71, and 78,|The occurrence of TG103 anti-drug antibodies (ADA), AD Aafter administration of of TG103, up to 15 weeks|Peak Plasma Concentration (Cmax),, PK parameters after administration of of TG103, Day1, 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78|Time to maximum plasma concentration (Tmax), PK parameters after administration of of TG103, Day1, 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78|Half time (t1/2),, PK parameters after administration of of TG103, Day1, 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78|Apparent clearance (CL/F), PK parameters after administration of of TG103, Day1, 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78
|
